Core Viewpoint - Antai Technology has become a leading enterprise in the advanced metal new materials sector in China, focusing on core business strengths and achieving steady growth in operating performance during the "14th Five-Year Plan" period [1][2]. Group 1: Business Performance - In the first half of 2025, Antai Technology achieved a revenue of 3.715 billion yuan and a net profit of 187 million yuan, despite pressures from overseas market fluctuations and rising raw material prices [2]. - The company saw significant growth in new contract amounts for its refractory tungsten and molybdenum business, as well as its magnetic materials business, indicating strong market demand [2][3]. - The company has undergone structural adjustments, exiting six companies and disposing of inefficient assets, which has contributed to its steady growth [2]. Group 2: Investment Focus - During the "14th Five-Year Plan," 63.44% of the company's investment was concentrated in the refractory alloy and rare earth permanent magnet sectors, which are crucial for its future high-quality development [3]. - The rare earth permanent magnet business has achieved a production capacity of high-end products at a scale of tens of thousands of tons, while the refractory alloy business has surpassed 2 billion yuan in operational scale [3][5]. Group 3: Technological Advancements - Antai Technology is a leader in the development of new materials, with significant advancements in applications across various industries, including new energy, aerospace, and medical health [4][5]. - The company has established itself as a major supplier of tungsten alloy components for radiation therapy equipment, holding a 70% market share globally [5]. - Antai Technology is also recognized for its innovations in amorphous and nanocrystalline materials, being the largest manufacturer of high-end nanocrystalline strip materials globally [6]. Group 4: International Expansion - Antai Technology has accelerated its global development, with nearly one-third of its revenue coming from exports, particularly in high-end rare earth materials and diamond tools [7][8]. - The company is actively developing clients in Southeast Asia and enhancing its international trade platform to support its global market strategy [8].

Core Viewpoint - The announcement details the resignation of Wang Tiejun, the Vice President of Antai Technology Co., Ltd., due to work adjustments, effective immediately upon notification to the board [1][2]. Group 1: Resignation Details - Wang Tiejun has submitted his resignation letter and will no longer hold any position within the company after his departure [1]. - He directly held 220,000 shares of the company at the time of the announcement and will manage his shares according to relevant regulations [1]. - The resignation is not expected to adversely affect the company's normal operations [1]. Group 2: Company Acknowledgment - The board expresses gratitude for Wang Tiejun's diligence and contributions to the company's development during his tenure [1].

证券代码：000969 证券简称：安泰科技 公告编号：2025-036 2、离任高管持股及减持承诺事项的说明。 特此公告 安泰科技股份有限公司（以下简称"公司"）董事会于近日收到公司副总经 理王铁军先生的离任告知函。王铁军先生因工作调整原因申请辞去公司副总经理 职务，辞职后将不再担任公司任何职务。根据《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》等相关规定，上述离任告知函自送达 董事会之日起生效。 截至本公告披露日，王铁军先生直接持有公司股份 220,000 股，王铁军先生 将严格按照相关规定管理其所持股份。王铁军先生不存在应当履行而未履行的其 他承诺事项，并已按照公司相关规定做好工作交接。 王铁军先生的离任不会对公司的正常生产经营产生不利影响。公司董事会 对王铁军先生在任职期内的勤勉尽责和为公司发展做出的贡献表示衷心的感谢！ 备查文件 1、王铁军先生出具的《离任告知函》； 安泰科技股份有限公司 关于公司副总经理离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 安泰科技股份有限公司董事会 2025 年 9 月 16 日 1 ...

转自：前瞻产业研究院 行业主要上市公司：九菱科技(873305.BJ);东睦股份(600114.SH);安泰科技(000969.SZ);海昌新材 (300885.SZ);杭齿前进(601177.SH)。 本文核心数据：粉末冶金行业竞争力评价;粉末冶金行业竞争梯队 1、中国粉末冶金行业竞争梯队 从中国粉末冶金参与者的业务收入情况来看，中国粉末冶金行业企业大致分为三个梯队。第一梯队的企 业是安泰科技，其营业收入较高，相关业务收入超过28亿元，在行业内的知名度和竞争力均较高，处于 行业领先地位;第二梯队是东睦股份，该企业与其相关业务收入相对较高，2023年业务收入接近20亿元; 第三梯队有天宜上佳、海昌新材、九菱科技、博云新材等，这些企业的业务收入在1-5亿元区间内。 2、中国粉末冶金行业竞争者入场进程 从中国粉末冶金行业代表性企业竞争者入场进程来看，大多数粉末冶金企业成立于2005年以前，其中华 金科技成立时间最早，于1993年成立，东睦股份和博云新材均成立于1994年。从企业注册资本情况来 看，安泰科技较高，注册资本达到10.26亿元人民币。 注：横轴代表企业成立年份;纵轴代表企业注册资本。 3、中国粉末冶金行 ...

Group 1 - The company, Antai Technology (000969.SZ), currently does not engage in solid-state battery business and has no equity participation in solid-state battery projects [1] - The only related product is the super porous activated carbon produced by its associate company, Antai Chuangming, which can be used for battery anode materials; however, this associate company is not consolidated in the financial statements [1]

每经AI快讯，有投资者在投资者互动平台提问：请问贵公司参股的固态电池项目进展如何了？及时发 布最新消息！ （记者 张明双） 安泰科技（000969.SZ）9月12日在投资者互动平台表示，公司产业目前暂不涉及固态电池业务，也没有 参股固态电池项目。据公司了解，目前只有参股公司安泰创明生产的超级多孔活性炭可以用于电池负极 材料，但该公司不并表。 ...

Group 1 - The company has successfully applied its tungsten-copper composite filter technology in the ITER international nuclear fusion project [1] - The company does not engage in the business of perfluorosulfonic acid proton membranes [1]

Group 1 - The first national 3D printing drug production license has been issued in Nanjing, marking a significant step in the development and industrialization of 3D printing technology in pharmaceuticals [2] - The licensed entity, Nanjing SanDieJi Pharmaceutical Technology Co., has a production capacity of 300 million 3D printed drug pieces annually, making it the largest commercial production base for 3D printed drugs globally [2] - 3D printing technology offers advantages over traditional pharmaceutical manufacturing, including complex drug structure design, digital drug development, precise drug delivery, and intelligent manufacturing [2] Group 2 - The 3D printing market in China is projected to reach approximately 423 billion yuan in 2024 and is expected to exceed 450 billion yuan by 2025, driven by the increasing application of 3D printing products and the release of pent-up demand for 3D printing equipment [3] - The application fields of 3D printing are expanding, covering industries such as aerospace, automotive, biomedical, construction, and consumer goods, with rapid growth in the consumer electronics sector [3] Group 3 - Seven 3D printing concept stocks have been frequently researched by institutions, with notable companies including Dazong Laser, Aobi Zhongguang-UW, and Yuedan New Materials, among others [5] - The average increase in the stock prices of 3D printing concept stocks this year is 37.05%, with Zhongzhou Special Materials leading with a 192% increase [5][6] - Companies like Aidi Te and Huazhu High-Tech are actively involved in the 3D printing sector, with Aidi Te having launched multiple 3D printers and Huazhu High-Tech developing its own 3D printing equipment and materials [4][5] Group 4 - Xie Chuang Data (300857) has seen its stock price rise significantly, reaching a market value of 44.303 billion yuan, with a maximum increase of over 11 times compared to its three-year low [7] - The company reported a revenue of 4.944 billion yuan in the first half of the year, a year-on-year increase of 38.18%, with a net profit of 432 million yuan, reflecting a growth of 20.76% [7]

Core Insights - Jiangsu Province has issued the first national drug production license utilizing 3D printing technology, marking a significant advancement in the research and industrialization of 3D printed pharmaceuticals in China [1] - The confidence of pharmaceutical companies in 3D printing technology is greatly encouraged by this development [1] Group 1: Market Performance - As of September 10, 2023, 3D printing concept stocks have seen an average increase of 37.05% this year [1] - Zhongzhou Special Materials has the highest increase at 192%, followed by Huazhu High-Tech with an increase of 111.02% [1] Group 2: Institutional Research - Seven 3D printing concept stocks have been investigated by institutions 10 times or more this year, including Dazhu Laser, Aobi Zhongguang-UW, and others [1] - Dazhu Laser leads with 72 institutional investigations, while Aobi Zhongguang-UW has been investigated 21 times [2]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [5]. Core Insights - The company's core industries remain resilient, with strong growth in high-end powder business despite a slight decline in overall revenue [1][2]. - The company has optimized its product structure and accelerated new product promotion, achieving significant growth in high-end medical equipment and semiconductor fields [2]. - The company has successfully completed key projects, maintaining its leading position in the refractory tungsten and molybdenum metal products industry [2]. Financial Performance - In H1 2025, the company achieved revenue of 3.715 billion yuan, a year-over-year decrease of 5.3%, and a net profit of 187 million yuan, down 33.2% year-over-year [1]. - The second quarter of 2025 saw revenue of 1.933 billion yuan, a decrease of 4.8% year-over-year but an increase of 8.4% quarter-over-quarter [1]. - The company’s net profit for Q2 2025 was 105 million yuan, down 48.1% year-over-year but up 26.8% quarter-over-quarter [1]. Segment Performance - The refractory tungsten and molybdenum business faced pressure due to overseas market fluctuations and rising raw material prices, but new contract signings increased significantly [2]. - The magnetic materials segment saw new contract amounts of 916 million yuan, a year-over-year increase of 9.9%, despite a revenue decline of 6.4% [3]. - The high-end powder segment continues to break through, with a new project partially in production, solidifying the company's position in the metal soft magnetic powder field [4]. Profit Forecast - The company’s profit forecast has been slightly adjusted upwards, with expected net profits for 2025-2027 at 353 million, 375 million, and 397 million yuan respectively, corresponding to P/E ratios of 41.7, 39.3, and 37.1 [4].